

Change in Aiforia Technologies Plc's Management Team

Aiforia Technologies Plc, Company Release, December 1, 2023 09:00 a.m. EET

Aiforia Technologies Plc reinforces its Management Team to strengthen the implementation of the company's growth strategy. Panu Kauppila has been appointed Chief Product Officer and a member of the Management Team (previously Vice President of Product Management) as of 1.12.2023. He has been with the company since June 2022. Panu has played a key role in defining Aiforia's product portfolio and prioritizing product development. In particular, he has led the definition, development, and delivery of clinical product portfolio.

Panu has more than 25 years of experience in productization and management of innovation in the medical technology sector in international companies. Before Aiforia, he has worked at Philips as an international product development director for radiotherapy and also for digital pathology solutions. He graduated from the Helsinki University of Technology with a degree in Medical Physics and Technology.

"We are expanding the management team to bring product management more closely into strategic decision-making. Panu has a profound understanding of how scalable products can be built on top of a software platform for demanding preclinical and clinical use. Another strength he has is the ability to identify relevant trends in the market and use this knowledge in product development," says Jukka Tapaninen, CEO of Aiforia.

After the appointment, the composition of Aiforia's Management Team is as follows:

Jukka Tapaninen, Chief Executive Officer

Kaisa Helminen, Chief Operating Officer

Kari Pitkänen, Director of Business Development

Tuomas Ropponen, Chief Technology Officer

Veli-Matti Parkkonen, Chief Financial Officer

Thomas Westerling-Bui, Vice President of AI Solutions & Strategy

Panu Kauppila, Chief Product Officer

More detailed information on the members of the Management Team are available on the company's website at <https://investors.aiforia.com/management-team>.

Further inquiries

Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33 61 041 6686
<https://investors.aiforia.com/>

Certified Adviser

UB Securities Ltd, tel. +358 9 25 380 225

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and

software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.

Find out more at www.aiforia.com